2023
Identification of a neutrophil-specific PIK3R1 mutation facilitates targeted treatment in a patient with Sweet syndrome
Bhattacharya S, Basu S, Sheng E, Murphy C, Wei J, Kersh A, Nelson C, Bryer J, Ashchyan H, Steele K, Forrestel A, Seykora J, Micheletti R, James W, Rosenbach M, Leung T. Identification of a neutrophil-specific PIK3R1 mutation facilitates targeted treatment in a patient with Sweet syndrome. Journal Of Clinical Investigation 2023, 133: e162137. PMID: 36355435, PMCID: PMC9797331, DOI: 10.1172/jci162137.Peer-Reviewed Original ResearchConceptsSteroid-sparing agentSweet's syndromeInflammatory diseasesCorticosteroid-related side effectsElevated IL-1Febrile neutrophilic dermatosisDramatic therapeutic responseReceptor 1 antagonistNeutrophil respiratory burstMultiorgan inflammatory diseasePersonalized medicine approachPI3K/AktSuccessful clinical interventionNeutrophilic dermatosisFrontline therapyRefractory casesNeutrophilic infiltrateBlood countIL-1βNeutrophil functionNeutrophil migrationTherapeutic responseLiver enzymesClinical challengeIL-1
2020
Cutaneous immune-related adverse events to checkpoint inhibitors
Malviya N, Tattersall IW, Leventhal J, Alloo A. Cutaneous immune-related adverse events to checkpoint inhibitors. Clinics In Dermatology 2020, 38: 660-678. PMID: 33341200, DOI: 10.1016/j.clindermatol.2020.06.011.Peer-Reviewed Original ResearchConceptsAdverse reactionsCheckpoint inhibitorsImmune-related adverse reactionsCheckpoint inhibitor therapyCutaneous adverse eventsOngoing cancer treatmentPD-1 inhibitorsCTLA-4 inhibitorsImmune checkpoint inhibitorsCutaneous adverse reactionsPD-L1 inhibitorsDevelopment of immunotherapySuch adverse reactionsImmunomodulatory therapyTreatment interruptionAssociated morbidityPatient comorbiditiesAdverse eventsCutaneous toxicityInhibitor therapyImmune statusHematologic malignanciesEarly recognitionCancer treatmentManagement guidelines
2018
Neutrophilic dermatoses Pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet disease
Nelson CA, Stephen S, Ashchyan HJ, James WD, Micheletti RG, Rosenbach M. Neutrophilic dermatoses Pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet disease. Journal Of The American Academy Of Dermatology 2018, 79: 987-1006. PMID: 29653210, DOI: 10.1016/j.jaad.2017.11.064.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAntineoplastic AgentsAutoimmune DiseasesBehcet SyndromeChemotaxis, LeukocyteCytokinesDermisDiagnosis, DifferentialDrug EruptionsEpidermisEthnicityGenetic Predisposition to DiseaseHidradenitisHumansImmunity, InnateImmunosuppressive AgentsInflammationNeoplasmsNeutrophilsSweet SyndromeVasculitisConceptsNeutrophilic eccrine hidradenitisNeutrophilic dermatosisSweet's syndromeBehçet's diseaseInflammatory skin disorderSignificant patient morbidityUnique clinical featuresMedical education seriesSystemic corticosteroidsBiologic agentsClinical featuresNeutrophilic infiltrateCutaneous lesionsHistopathologic featuresPatient morbidityTherapeutic modalitiesNeoplastic processSkin disordersDermatosesHeterogeneous groupDiseaseDiagnosisHidradenitisDisordersSyndrome
2017
Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center
Nelson CA, Noe MH, McMahon CM, Gowda A, Wu B, Ashchyan HJ, Perl AE, James WD, Micheletti RG, Rosenbach M. Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center. Journal Of The American Academy Of Dermatology 2017, 78: 303-309.e4. PMID: 29107342, DOI: 10.1016/j.jaad.2017.09.013.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdrenal Cortex HormonesAdultAgedAnemiaArthralgiaColchicineDapsoneFemaleFilgrastimfms-Like Tyrosine Kinase 3Folic Acid AntagonistsHematologic AgentsHumansInflammationLeukemia, Myeloid, AcuteLeukopeniaMaleMiddle AgedMutationNeoplasmsNuclear ProteinsNucleophosminPotassium IodideRetrospective StudiesSweet SyndromeTertiary Care CentersThrombocytopeniaTubulin ModulatorsConceptsTertiary academic referral centerAbsence of arthralgiaDrug-induced formsSweet's syndromeAcademic referral centerReferral centerSingle tertiary academic referral centerSetting of malignancyAcute myeloid leukemiaConcurrent malignancyNeutrophilic dermatosisClinicopathologic characteristicsCommon medicationsCommon malignancyRetrospective studyMyeloid leukemiaRetrospective analysisRare disorderPatientsMalignancySyndromePotential associationArthralgiaLeukopeniaThrombocytopeniaTumor Necrosis Factor-α and IL-17A Activation Induces Pericyte-Mediated Basement Membrane Remodeling in Human Neutrophilic Dermatoses
Lauridsen HM, Pellowe AS, Ramanathan A, Liu R, Miller-Jensen K, McNiff JM, Pober JS, Gonzalez AL. Tumor Necrosis Factor-α and IL-17A Activation Induces Pericyte-Mediated Basement Membrane Remodeling in Human Neutrophilic Dermatoses. American Journal Of Pathology 2017, 187: 1893-1906. PMID: 28609645, PMCID: PMC5530916, DOI: 10.1016/j.ajpath.2017.04.008.Peer-Reviewed Original ResearchConceptsSweet's syndromeIL-17ATumor necrosis factorMatrix metalloproteinasesNeutrophilic dermatosisNeutrophil recruitmentNecrosis factorMMP-3Basement membraneDermal postcapillary venulesIL-17A activationPrototypical neutrophilic dermatosisVascular wall integrityCollagen IV productionExpression of fibronectinActive matrix metalloproteinasesMicrovascular changesInflammatory diseasesSkin biopsiesFibronectin levelsHuman pericytesMicrovascular remodelingHistologic analysisPostcapillary venulesTNF
2015
Skin Signs of Rheumatoid Arthritis and its Therapy-Induced Cutaneous Side Effects
Xue Y, Cohen JM, Wright NA, Merola JF. Skin Signs of Rheumatoid Arthritis and its Therapy-Induced Cutaneous Side Effects. American Journal Of Clinical Dermatology 2015, 17: 147-162. PMID: 26649439, DOI: 10.1007/s40257-015-0167-z.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAntirheumatic AgentsArthritis, RheumatoidBiological TherapyDermatomyositisDrug EruptionsHumansLichenoid EruptionsLupus Erythematosus, CutaneousMelanomaPyoderma GangrenosumRheumatoid NoduleRheumatoid VasculitisSkin DiseasesSkin NeoplasmsSweet SyndromeTumor Necrosis Factor-alphaConceptsRheumatoid arthritisAdverse effectsBiologic disease-modifying agentsManagement of RAAnti-TNFα agentsRA disease activityCutaneous adverse effectsSystemic inflammatory disorderCutaneous side effectsDisease-modifying agentsGranulomatous skin disorderConnective tissue disordersNeutrophilic dermatosisRheumatoid vasculitisDisease activityAggressive treatmentRheumatoid nodulesCutaneous findingsClinical presentationTherapeutic challengeGranulomatous conditionsInflammatory disordersSkin signsCutaneous diseaseCutaneous effects
2000
Sweet's syndrome and Pneumocystis carinii pneumonia: two sequelae of low‐dose cytosine arabinoside therapy in a patient with acute myeloid leukemia
Chowdhary V, Nityanand S, Prasad K, Pandey R, Dabadghao S. Sweet's syndrome and Pneumocystis carinii pneumonia: two sequelae of low‐dose cytosine arabinoside therapy in a patient with acute myeloid leukemia. European Journal Of Haematology 2000, 65: 72-73. PMID: 10914942, DOI: 10.1034/j.1600-0609.2000.9c177.x.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaPneumocystis carinii pneumoniaMyeloid leukemiaCarinii pneumoniaLow‐dose cytosine arabinoside therapyAcute febrile neutrophilic dermatosisAttainment of remissionFebrile neutrophilic dermatosisLow-dose cytosineNeutrophilic dermatosisSweet's syndromeImmunosuppressive potentialNeutrophil functionLow doseLow dosesLeukemiaPneumoniaSyndromeDirect effectRemissionSequelaePatientsDermatosesTherapyDose
1998
Clinicopathology conferences: Inflammation‐induced cholestasis
Crawford J, Boyer J. Clinicopathology conferences: Inflammation‐induced cholestasis. Hepatology 1998, 28: 253-260. PMID: 9657120, DOI: 10.1002/hep.510280133.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply